Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 136Unknown 40Recruiting 33Terminated 28Active not recruiting 20Withdrawn 10Not yet recruiting 9Enrolling by invitation 4Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Neoplasms 46Breast Neoplasms 46Colorectal Neoplasms 27Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Glioblastoma 19Melanoma 17Lung Neoplasms 17Pancreatic Neoplasms 16Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Ovarian Neoplasms 13Brain Neoplasms 13Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Triple Negative Breast Neoplasms 10Multiple Myeloma 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 10Lymphoma 9Uterine Cervical Neoplasms 7Sarcoma 7Rectal Neoplasms 7Leukemia 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Gallbladder Neoplasms × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡